drug-pricing
(11)
ConnectureDRX knows why the cheapest Medicare premium can be expensive
A medicine cabinet can tell you more about a Medicare plan than its price tag. ConnectureDRX turns those small, personal details into comparisons, enrollments, and a reason to call again next year.
RxSense and the Price Behind the Price
A prescription can have several prices before it reaches the counter. RxSense builds the machinery that helps consumers compare them - and lets organizations run more of the pharmacy benefit themselves.
The Pharmacy Middleman Who Put His Fee on the Table
SmithRx makes its money from an administrative fee, then goes looking for cheaper drugs. In a business famous for invisible margins, that small change alters what the middleman is paid to do.
Waxman Strategies Put a Velvet Rope Around Influence
In Washington, access is usually sold to whoever can pay. Michael Waxman built a firm around a narrower proposition: policy, advocacy and communications for work it can defend in public.
Lyfegen
Lyfegen is a Swiss health-tech company that builds software to manage value-based drug pricing and rebate agreements. Its platform helps health insurers, governments, hospital payers, pharmaceutical firms and medical device makers automate complex rebate contracts, run pricing simulations and tap the world's largest library of value-based agreements - reducing administrative burden while helping patients access innovative therapies.
Truveris
Truveris is a healthcare technology company that helps employers, benefits consultants and plan sponsors buy and oversee pharmacy benefits. Founded in 2009 and based in Wilmington, Delaware, it runs a competitive procurement marketplace connecting buyers with 60-plus pharmacy benefit managers, analyzes 100% of pharmacy claims to police PBM contract performance, and layers on independent audits and member engagement tools. The company says clients typically see roughly 20% improvement on pharmacy contract costs.
Girisha Fernando
Girisha Fernando is the CEO and co-founder of Lyfegen, a Basel- and Boston-based healthtech company building software that helps payers, hospitals, pharma companies and medical device makers manage value-based drug pricing, access and rebate agreements. After nearly a decade at Roche in market access, pricing and IT, he left in 2018 to build technology that ties the price of medicine to how well it actually works for patients. He splits his time between Switzerland and New York as Lyfegen pushes into the US market.
Catalina Gorla
Catalina Gorla is the co-founder and CEO of TruDataRx, a Vermont-based health technology company that helps self-insured employers cut pharmacy spend using objective clinical data and comparative-effectiveness analytics. A Dartmouth-educated former economist turned healthcare entrepreneur, she has spent over a decade attacking the hidden costs and conflicts of interest baked into American drug pricing. She previously co-founded Informulary, managed innovation programs at the Dartmouth Center for Healthcare Delivery Science, and delivered a TEDxBeaconStreet talk arguing the U.S. doesn't need a single payer so much as an informed one.
Geoffrey Chaiken
Geoffrey Chaiken is the co-founder and CEO of BlinkRx (Blink Health), a New York-based digital health company rebuilding how prescription drugs get priced, paid for, and delivered. The son and grandson of physicians, he gave up a career in medicine to attack what he calls the real bottleneck in healthcare - not discovering new cures, but getting existing ones into patients' hands at a fair price. With his younger brother Matthew, he has raised more than half a billion dollars to digitize both the patient front end and the pharmaceutical industry's back end, partnering with drug makers and tens of thousands of pharmacies to strip middlemen out of the medication supply chain.
Alex Brill
Alex Brill is a Washington economist who turns tax code arcana into arguments lawmakers actually use. He is the founder and CEO of Matrix Global Advisors, a boutique economic consulting firm, and a senior fellow at the American Enterprise Institute. Before going independent he was policy director and chief economist of the House Ways and Means Committee and served on the White House Council of Economic Advisers. He edits and writes books on tax policy, testifies before Congress, and works the seam between tax, health care, and fiscal policy.
Bobn L
Bobn L is the Chief Executive Officer of GoodRx, the Santa Monica-based digital health company that has become America's most-used prescription savings platform. GoodRx tracks drug prices across 75,000+ pharmacies nationwide, delivering coupons and transparency to millions of Americans navigating the opaque world of prescription pricing. Under executive leadership, GoodRx has grown to nearly $800 million in annual revenue, gone public on Nasdaq (GDRX), and expanded into telemedicine - all in service of a single idea: that patients deserve to know what their medications actually cost.